BioCentury
ARTICLE | Targets & Mechanisms

CXCR2 antagonists in breast cancer

August 9, 2012 7:00 AM UTC

A team at the Memorial Sloan-Kettering Cancer Center has shown that CXC chemokine receptor 2 antagonists sensitized tumors to chemotherapy in mouse models of metastatic breast cancer.1 The team is working on additional preclinical studies with the intention of moving the antagonists into clinical trials for breast cancer.

Resistance to chemotherapy often occurs in breast cancer as a result of a small percentage of cancer cells that develop a survival advantage and show a more aggressive, metastatic phenotype...